The week in pharma: action, reaction and insight – week to July 5, 2024
By Barbara Obstoj-Cardwell. Editor
Research news was prominent last week, first with US healthcare giant Johnson & Johnson presenting new data on nipocalimab in the treatment of generalized myasthenia gravis (MS), pitching it against argenx’ Fc Rn blocker Vyvgart. Cartesian Therapeutics also reported positive top-line results for Descartes-08 in patients with myasthenia gravis, as well as a $130 financing. However, Roche released disappointing Phase II/III clinical trial results for its tiragolumab in combination with Tecentriq for non-small cell lung cancer (NSCLC), leading the Swiss pharma giant to halt the study. On the regulatory front, Eli Lilly gained long-awaited approval from the US Food and Drug Administration for its Alzheimer’s disease drug donanemab, to be marketed by the US pharma major under the trade name Kisunla.
J&J: Nipocalimab benefit/risk in MG questionable vs Vyvgart
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze